Glembatumumab Vedotin (CDX-011, CR011-vcMMAE): On The Brink Of Targeted Therapy For Triple-Negative Breast Cancer?
Journal of Clinical Oncology (JCO) Podcast · Journals Online Team
September 29, 201411m 47s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A phase I/II study of the antibody-drug conjugate glembatumumab vedotin (CDX-011 or CR011-vcMMAE) in patients with locally advanced or metastatic breast cancer, reveals an acceptable safety profile and promising clinical activity in GPNMB expressing breast cancer.